Summary
Global Markets Direct’s, ‘Cancer Cachexia - Pipeline Review, H2 2016’, provides an overview of the Cancer Cachexia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cancer Cachexia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Cachexia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
- The report reviews pipeline therapeutics for Cancer Cachexia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cancer Cachexia therapeutics and enlists all their major and minor projects
- The report assesses Cancer Cachexia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cancer Cachexia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Acacia Pharma Limited
Aeterna Zentaris Inc.
Aphios Corporation
Atara Biotherapeutics, Inc.
Eli Lilly and Company
Helsinn Healthcare S.A.
Incyte Corporation
Lakewood-Amedex Inc
Novartis AG
Obexia AG
PsiOxus Therapeutics Limited
RaQualia Pharma Inc.
Viking Therapeutics, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cancer Cachexia Overview 9
Therapeutics Development 10
Pipeline Products for Cancer Cachexia - Overview 10
Pipeline Products for Cancer Cachexia - Comparative Analysis 11
Cancer Cachexia - Therapeutics under Development by Companies 12
Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes 14
Cancer Cachexia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Cancer Cachexia - Products under Development by Companies 18
Cancer Cachexia - Products under Investigation by Universities/Institutes 19
Cancer Cachexia - Companies Involved in Therapeutics Development 20
Acacia Pharma Limited 20
Aeterna Zentaris Inc. 21
Aphios Corporation 22
Atara Biotherapeutics, Inc. 23
Eli Lilly and Company 24
Helsinn Healthcare S.A. 25
Incyte Corporation 26
Lakewood-Amedex Inc 27
Novartis AG 28
Obexia AG 29
PsiOxus Therapeutics Limited 30
RaQualia Pharma Inc. 31
Viking Therapeutics, Inc. 32
Cancer Cachexia - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(formoterol fumarate + megestrol acetate) - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
anamorelin hydrochloride - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ATA-842 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
AUSRM-057 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
bimagrumab - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
DLN-101 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
dronabinol - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
espindolol - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
EXT-400 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Foxo1-nRNA - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
HM-03 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
landogrozumab - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
macimorelin acetate - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
OBX-1201 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
RQ-00433412 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
ruxolitinib phosphate - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Synthetic Peptide to Antagonize Melanocortin Receptor for Cancer Cachexia - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Synthetic Peptides for Cancer Cachexia - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
tertomotide - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
VK-5211 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Cancer Cachexia - Dormant Projects 92
Cancer Cachexia - Discontinued Products 94
Cancer Cachexia - Product Development Milestones 95
Featured News & Press Releases 95
Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer 95
Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology 96
Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology 98
Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102 99
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 100
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 100
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 101
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 102
Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia 102
Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102 103
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 104
Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June 105
Dec 15, 2005: Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia 105
Jan 10, 2005: Rejuvenon's RC-1291 Ghrelin Mimetic Receives Fast Track Designation From FDA for Cancer Anorexia/Cachexia 106
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108
List of Tables
Number of Products under Development for Cancer Cachexia, H2 2016 10
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Cancer Cachexia - Pipeline by Acacia Pharma Limited, H2 2016 20
Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2016 21
Cancer Cachexia - Pipeline by Aphios Corporation, H2 2016 22
Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2016 23
Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2016 24
Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2016 25
Cancer Cachexia - Pipeline by Incyte Corporation, H2 2016 26
Cancer Cachexia - Pipeline by Lakewood-Amedex Inc, H2 2016 27
Cancer Cachexia - Pipeline by Novartis AG, H2 2016 28
Cancer Cachexia - Pipeline by Obexia AG, H2 2016 29
Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2016 30
Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H2 2016 31
Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2016 32
Assessment by Monotherapy Products, H2 2016 33
Assessment by Combination Products, H2 2016 34
Number of Products by Stage and Target, H2 2016 36
Number of Products by Stage and Mechanism of Action, H2 2016 39
Number of Products by Stage and Route of Administration, H2 2016 42
Number of Products by Stage and Molecule Type, H2 2016 44
Cancer Cachexia - Dormant Projects, H2 2016 92
Cancer Cachexia - Dormant Projects (Contd..1), H2 2016 93
Cancer Cachexia - Discontinued Products, H2 2016 94
List of Figures
Number of Products under Development for Cancer Cachexia, H2 2016 10
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 33
Number of Products by Top 10 Targets, H2 2016 35
Number of Products by Stage and Top 10 Targets, H2 2016 35
Number of Products by Top 10 Mechanism of Actions, H2 2016 38
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38
Number of Products by Routes of Administration, H2 2016 41
Number of Products by Stage and Routes of Administration, H2 2016 41
Number of Products by Molecule Types, H2 2016 43
Number of Products by Stage and Molecule Types, H2 2016 43
